S&P Futures
5,887.50 -5.00 (-0.08%) Dow Futures
43,044.00 -125.00 (-0.29%) Nasdaq Futures
20,520.00 -22.00 (-0.11%) Russell 2000 Futures
2,246.10 -0.10 (-0.00%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,760.30 +0.50 (+0.02%)
Alphamab Oncology (9966.HK)
| Previous Close | 3.840 |
| Open | 3.850 |
| Bid | 3.720 x N/A |
| Ask | 3.740 x N/A |
| Day's Range | 3.690 - 3.880 |
| 52 Week Range | 2.000 - 13.460 |
| Volume | |
| Avg. Volume | 4,099,757 |
| Market Cap | 3.601B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.250 |
| Earnings Date | Aug 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.06 |
Simply Wall St.Exploring High Growth Tech Stocks In Hong Kong
As global markets experience shifts with interest rate adjustments and economic indicators showing mixed signals, the Hong Kong market remains a focal point for investors seeking opportunities in high-growth tech sectors. In this dynamic environment, identifying promising stocks often involves assessing companies that not only demonstrate robust innovation and adaptability but also align well with prevailing market trends and economic conditions.
PR NewswireIND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound Docetaxel HB1801 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer.
